High Von Willebrand Factor linked to poor prognosis of breast cancer patients

Published On 2022-07-05 14:30 GMT   |   Update On 2022-07-05 14:30 GMT

New research from RCSI University of Medicine and Health Sciences has found that high levels in the bloodstream of a key protein involved in blood clotting called von Willebrand Factor, can lead to poorer outcomes for breast cancer patients. The findings will help researchers and doctors to better understand and treat breast cancer to reduce the risk of life-threatening blood clots and...

Login or Register to read the full article

New research from RCSI University of Medicine and Health Sciences has found that high levels in the bloodstream of a key protein involved in blood clotting called von Willebrand Factor, can lead to poorer outcomes for breast cancer patients. The findings will help researchers and doctors to better understand and treat breast cancer to reduce the risk of life-threatening blood clots and cancer spread in patients.

Published in the Journal of Thrombosis and Haemostasis, the research found that patients with breast cancer had very high levels of von Willebrand Factor in their blood and that patients with the highest levels had the poorest outcomes. This work suggests that analysis of von Willebrand Factor levels may be useful to help predict clinical outcomes in patients with breast cancer.

The study also examined how breast cancer triggers high levels of von Willebrand Factor and found that breast tumour cells cause release of the clotting protein which helps the breast tumour cells to circulate in the blood stream and may aid breast tumour spreading to other organs in the body. Anticoagulant medication or blood-thinners which are already used to treat blood clots, could inhibit this effect by reducing levels of von Willebrand Factor and also preventing the spread of cancer cells in the blood stream.

The findings of the research will help doctors to better understand why patients with breast cancer have increased risk of blood clots and also why this may contribute to worse disease, cancer progression and spread throughout the body.

Dr Jamie O'Sullivan, Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, RCSI, said: "There are over 2 million people worldwide diagnosed with breast cancer every year, making it the world's most prevalent cancer. Importantly, it is not the primary breast tumour, but its spread to distant sites in the body such as bone, brain and lungs that are the main cause of death.

In addition, as they spread via the bloodstream, these breast cancer cells cause blood clotting in approximately 1 in 5 patients, which increases their risk of life-threatening complications.

"Our findings now show, for the first time, that this blood clotting may be caused by increased levels of a key pro-clotting protein, von Willebrand Factor, and that the breast tumour cells directly interact with the blood vessel wall to promote release of this protein. Interestingly, this not only increases risk of blood clotting for these patients but may also promote breast cancer cells spreading throughout the body via the circulation.

Our work helps to better understand why patients with breast cancer have increased risk of blood clots and also why this may contribute to worse disease, cancer progression and spread throughout the body which will have a huge impact on the treatment of breast cancer and the outcomes for patients worldwide."

Reference:

Breast cancer cells mediate endothelial cell activation, promoting von Willebrand Factor release, tumour adhesion and transendothelial migration. Sukhraj Pal Singh Dhami, Sean Patmore, Claire Comerford, Ciara M. Byrne, Brenton Cavanagh, John Castle, Cliona C. Kirwan, Martin Kenny, Ingmar Schoen, James S. O'Donnell, Jamie M. O'Sullivan First published: 20 June 2022 https://doi.org/10.1111/jth.15794

Tags:    
Advertisement
Article Source : Journal of Thrombosis and Haemostasis

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News